HABA Laboratories, Inc. (JP:4925)
:4925
Top Page
HABA Laboratories, Inc.
(4925)
Select Model
Select Model
Rating:69Neutral
Price Target:
¥1,970.00
▲(18.67% Upside)
Action:ReiteratedDate:03/24/26
The score is driven primarily by improved FY2025 profitability and cash flow alongside a conservatively positioned balance sheet, tempered by recent revenue contraction and historical volatility. Technicals are mildly supportive, and valuation is reasonable with a moderate dividend yield.
Positive Factors
Conservative balance sheet
Low financial leverage (debt ~0.20x equity) and a substantial equity base provide durable financial flexibility. This conservative capital structure reduces insolvency risk, supports incremental investment or buybacks, and helps the company absorb shocks while pursuing its turnaround over the next several quarters.
Negative Factors
Revenue contraction
A persistent top-line decline (≈-1.9% YoY in FY2025) undermines scale advantages and limits the ability to absorb fixed costs. If revenue contraction continues, it could cap long-term margin expansion, constrain reinvestment, and slow the pace of the company’s recovery across multiple quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Low financial leverage (debt ~0.20x equity) and a substantial equity base provide durable financial flexibility. This conservative capital structure reduces insolvency risk, supports incremental investment or buybacks, and helps the company absorb shocks while pursuing its turnaround over the next several quarters.
Read all positive factors
HABA Laboratories, Inc. (4925) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥6.80B
Dividend Yield2.38%
Average Volume (3M)2.14K
Price to Earnings (P/E)12.5
Beta (1Y)0.26
Revenue Growth-0.79%
EPS GrowthN/A
CountryJP
Employees631
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)34.53
Shares Outstanding3,935,000
10 Day Avg. Volume2,940
30 Day Avg. Volume2,136
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)0.74
Price to Sales (P/S)0.55
P/FCF Ratio4.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
HABA Laboratories, Inc. Business Overview & Revenue Model
Company Description
HABA Laboratories,Inc. manufactures and sells skin care, and hair and body care products in Japan and internationally. Its skin care products include cleansers/face washes, toners, special care products, and squalane oils; and hair and body care p...
How the Company Makes Money
null...
HABA Laboratories, Inc. Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
78
Positive
Cash Flow
68
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.02B | 12.06B | 12.32B | 12.04B | 12.91B | 14.31B |
| Gross Profit | 8.08B | 7.99B | 8.03B | 8.17B | 8.79B | 10.20B |
| EBITDA | 826.86M | 811.56M | -1.31B | 17.05M | 448.30M | 960.14M |
| Net Income | 638.78M | 576.57M | -2.12B | -707.87M | -269.03M | 216.42M |
Balance Sheet | ||||||
| Total Assets | 11.76B | 12.34B | 12.43B | 14.73B | 15.76B | 17.52B |
| Cash, Cash Equivalents and Short-Term Investments | 4.48B | 4.74B | 3.96B | 4.82B | 5.65B | 5.66B |
| Total Debt | 1.56B | 1.82B | 2.36B | 2.03B | 2.56B | 3.92B |
| Total Liabilities | 2.95B | 3.42B | 3.92B | 3.96B | 4.12B | 5.48B |
| Stockholders Equity | 8.82B | 8.93B | 8.51B | 10.77B | 11.64B | 12.04B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 1.48B | -1.02B | -232.69M | 1.53B | -346.95M |
| Operating Cash Flow | 0.00 | 1.62B | -587.92M | 55.96M | 1.71B | 534.71M |
| Investing Cash Flow | 0.00 | -147.18M | -441.79M | -214.40M | -216.49M | -925.08M |
| Financing Cash Flow | 0.00 | -689.49M | 171.06M | -676.32M | -1.51B | 825.38M |
HABA Laboratories, Inc. Technical Analysis
Neutral
1660.00
Price Trends
1767.94
Positive
1723.89
Positive
1708.56
Positive
Market Momentum
8.67
Positive
51.68
Neutral
9.70
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4925, the sentiment is Neutral. The current price of 1660 is below the 20-day moving average (MA) of 1814.05, below the 50-day MA of 1767.94, and below the 200-day MA of 1708.56, indicating a neutral trend. The MACD of 8.67 indicates Positive momentum. The RSI at 51.68 is Neutral, neither overbought nor oversold. The STOCH value of 9.70 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4925.
HABA Laboratories, Inc. Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | ¥6.80B | 12.52 | ― | 2.38% | -0.79% | ― | |
68 Neutral | ¥2.15B | 3.43 | ― | 1.72% | -6.06% | -97.12% | |
64 Neutral | ¥19.32B | 33.88 | ― | 0.91% | 13.12% | 27.53% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
58 Neutral | ¥5.69B | -33.12 | ― | 1.68% | 8.46% | ― | |
58 Neutral | ¥7.79B | -49.92 | ― | 2.65% | 11.87% | -31.02% | |
51 Neutral | ¥2.02B | -3.04 | ― | ― | 12.96% | ― |
* Consumer Defensive Sector Average
JP:4925
HABA Laboratories, Inc.
1,799.00
-29.70
-1.62%
JP:4918
Ivy Cosmetics Corporation
355.00
107.00
43.15%
JP:4920
Nippon Shikizai, Inc.
1,020.00
-97.85
-8.75%
JP:4926
C'BON COSMETICS Co., Ltd.
1,333.00
154.80
13.14%
JP:4933
I-ne CO., LTD.
1,086.00
-588.58
-35.15%
JP:4936
AXXZIA, Inc.
333.00
-139.92
-29.59%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.